

BIBLIOGRAPHY

1. Schifano, F. (2009) Drug Abuse: Treatment and Management, in Substance Abuse Disorders (eds H. Ghodse, H. Herrman, M. Maj and N. Sartorius), John Wiley & Sons, Ltd, Chichester, UK.
doi: 10.1002/9780470975084.ch3
2. WHO | Other psychoactive substances [Internet]. [cited 2016 Sep 20]. Available from:
http://www.who.int/substance_abuse/facts/psychoactives/en/
3. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Drug Abuse and Dependence in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2007 May 1;64(5):566.
4. Sussman S, Lisha N, Griffiths M. Prevalence of the Addictions: A Problem of the Majority or the Minority? *Eval Health Prof*. 2011 Mar 1;34(1):3–56.
5. Poznyak VB, White J, Clark N. Drug Abuse: Prevention. In: Substance Abuse Disorders [Internet]. John Wiley & Sons, Ltd; 2009. p. 27–51. Available from: <http://dx.doi.org/10.1002/9780470975084.ch2>
6. Warner, L.A., Canino, G. and Colon HM (2001) Prevalence and correlates of substance-use disorders among older adolescents in Puerto Rico and the United States: a cross-country comparison. *Drug Alcohol Depend*, 63 (3), 229–243
7. Terracciano A, Löckenhoff CE, Crum RM, Bienvenu OJ, Costa PT. Five-Factor Model personality profiles of drug users. *BMC Psychiatry*. 2008;8:22. doi:10.1186/1471-244X-8-22.
8. VandenBos, G. R. (2007). *APA dictionary of psychology*. Washington, DC: APA
9. Page C, Michael C, Sutter M, Walker M, Hoffman BB (2002). *Integrated Pharmacology* (2nd ed.). C.V. Mosby.
10. Wit H; Griffiths RR (June 1991). "Testing the abuse liability of anxiolytic and hypnotic drugs in humans". *Drug and Alcohol Dependence*. **28** (1): 83–111. doi:10.1016/0376-8716(91)90054-3.

11. Joseph G. Benzodiazepine Abuse Basics [Internet]. WebMD. [cited 2015 Jun 2]. Available from: <http://www.webmd.com/mental-health/addiction/benzodiazepine-abuse>
12. Petrovic, M., Vandierendonck, A., Mariman, A., van Maele, G., Afschrift, M. and Pevernagie, D. (2002), Personality traits and socio-epidemiological status of hospitalised elderly benzodiazepine users. *Int. J. Geriatr. Psychiatry*, 17: 733–738. doi:10.1002/gps.677
13. SCHWEIZER, E., RICKELS, K., De MARTINIS, N., CASE, G. and GARCÍA-ESPAÑA, F. (cited 2016-10-24) ‘The effect of personality on withdrawal’ severity and taper outcome in benzodiazepine dependent patients’, *Psychological Medicine*, 28(3), pp. 713–720.
14. SCHNEIDER JR., Ricardo et al. Temperament and character traits associated with the use of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens: vol.37, n.1 [cited 2016-10-24], pp.31-39. 4446. <http://dx.doi.org/10.1590/1516-4446-2014-1352>.
15. WHO | Substance abuse [Internet]. WHO. [cited 2015 Jun 1]. Available from: http://www.who.int/topics/substance_abuse/en/
16. NIDA - Drug Abuse and Addiction: One of America's Most Challenging Public Health Problems
17. Etiology | Pathways of Addiction: Opportunities in Drug Abuse Research | The National Academies Press [Internet]. [cited 2016 Oct 11]. Available from: <https://www.nap.edu/read/5297/chapter/7#126>
18. Koob, George F., and Eric J. Simon. “The Neurobiology of Addiction: Where We Have Been and Where We Are Going.” *Journal of drug issues* 39.1 (2009): 115–132. Print.
19. Koob GF. Drugs of abuse: Anatomy, pharmacology, and function of reward pathways. *Trends in Pharmacological Sciences*. 1992;13:177–184
20. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology*. 2001;24:97–129.
21. Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: A role in activation, arousal, and affect regulation. *Journal of Pharmacology and Experimental Therapeutics*. 2004;311:427–440.

22. Heilig M, Koob GF, Ekman R, Britton KT. Corticotropin-releasing factor and neuropeptide Y: Role in emotional integration. *Trends in Neurosciences*. 1994;17:80–85
23. Koob GF, Le Moal M. Addiction and the brain antireward system. *Annual Review of Psychology*. 2008;59:29–53.
24. Bevilacqua L, Goldman D. Genes and Addictions. *Clinical pharmacology and therapeutics*. 2009;85(4):359-361. doi:10.1038/clpt.2009.6.
25. Etiology | Pathways of Addiction: Opportunities in Drug Abuse Research | The National Academies Press [Internet]. [cited 2016 Oct 11]. Available from: <https://www.nap.edu/read/5297/chapter/7#126>
26. Srivastava, V. and Goldman, D. (2011) Imaging Genetics and Addiction, in *Neuroimaging in Addiction* (eds B. Adinoff and E. A. Stein), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119998938.ch12
27. Arnold, M, and Joan, E. Treating Alcohol and Drug Problems in Psychotherapy Practice Doing What Works. *New York: Guilford Publications*. 2011. p. 47..
28. Page C, Michael C, Sutter M, Walker M, Hoffman BB (2002). *Integrated Pharmacology* (2nd ed.). C.V. Mosby.
29. Dikeos DG, Theleritis CG, Soldatos CR (2008). "Benzodiazepines: effects on sleep". In Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ. *Sleep Disorders: Diagnosis and Therapeutics*. Informa Healthcare. pp. 220–2.
30. C Heather Ashton, DM, FRCP. Guidelines for the Rational Use of Benzodiazepines : When and What to Use. Clinical Psychopharmacology Unit, Department of Psychiatry The Royal Victoria Infirmary Queen Victoria Road Newcastle upon Tyne NE1 4LP;
31. Olsen RW, Betz H (2006). "GABA and glycine". In Siegel GJ, Albers RW, Brady S, Price DD. *Basic Neurochemistry: Molecular, Cellular and Medical Aspects* (7th ed.). Elsevier. pp. 291–302.

32. Rudolph U, Möhler H (February 2006). "GABA-based therapeutic approaches: GABA_A receptor subtype functions". *Current Opinion in Pharmacology*. **6** (1): 18–23. *doi:10.1016* .
33. Ashton H (2005). "*The diagnosis and management of benzodiazepine dependence*" (PDF). *Current Opinion in Psychiatry*. **18** (3): 249–55. *doi:10.1097/01.yco.0000165594.60434.84*.
34. Lilly SM, Zeng XJ, Tietz EI: Role of protein kinase A in GABA_A receptor dysfunction in CA1 pyramidal cells following chronic benzodiazepine treatment. *J Neurochem* 2003, 85:988-998.
35. Hoseinifar J, Zirak SR, Shaker A, Meamar E, Moharami H, Siedkalan MM. Comparison of Quality of Life and Mental Health of Addicts and Non- Addicts. *Procedia - Soc Behav Sci*. 2011;30:1930–4.
36. Abraham J. Twerski, Craig Nakken. Addictive Thinking and the Addictive Personality [Internet]. Fine Communications; 1999. Available from: https://books.google.co.uk/books?id=z5_QPQAACAAJ
37. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW (2008): Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. *Philos Trans R Soc Lond B Biol Sci* 363:3125–3135.
38. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, *et al.* (1998): Familial transmission of substance use disorders. *Arch Gen Psychiatry* 55:973–979. □
39. deWitH(2009):Impulsivityasadeterminantandconsequenceofdrug use: A review of underlying processes. *Addict Biol* 14:22–31.
40. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton JH (2009): Fifty years of the Barratt Impulsiveness Scale: An update and review. *Pers Individ Dif* 47:385–395. □
41. Moeller FG, Barratt ES, Dougherty DM, *et al.* Psychiatric aspects of impulsivity. *Am J Psychiatry*. 2001;158(11):1783–93
42. Spear LP. The adolescent brain and age-related behavioral manifestations. *Neurosci Biobehav Rev*. 2000; 24(4):417–63.
43. MacKillop J, Kahler CW. Delayed reward discounting predicts treatment response for heavy drinkers receiving smoking cessation treatment. *Drug Alcohol Depend*. 2009; 104(3):197–203.

44. The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) [Internet]. [cited 2016 Oct 16]. Available from: <http://occmmed.oxfordjournals.org/content/59/2/135>
45. Sellbom M, Fischler GL, Ben-Porath YS. Identifying MMPI-2 predictors of police officer integrity and misconduct. *Crim Justice Behav* 2007; 34: 985–1004
46. Butcher JN, Dahlstrom WG, Graham JR, Tellegen AM, Kreamer B. The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Manual for Administration and Scoring Minneapolis, MN: University of Minneapolis Press, 1989
47. Olfson M, King M, Schoenbaum M. Benzodiazepine Use in the United States. *JAMA Psychiatry*. 2015;72(2):136-142. doi:10.1001/jamapsychiatry.2014.1763
48. Cooperstock R, Hill J. The effects of tranquilization: Benzodiazepine use in Canada. Ottawa (ON): Health Canada; 1982
49. Amodei N, Williams JF, Seale JP, Alvero ML. Gender differences in medical presentation and detection of patients with history of alcohol abuse or dependence. *J Addict Dis* 1996;15 (1):19-31
50. Petrovic, M., Vandierendonck, A., Mariman, A., van Maele, G., Afschrift, M. and Pevernagie, D. (2002), Personality traits and socio-epidemiological status of hospitalised elderly benzodiazepine users. *Int. J. Geriatr. Psychiatry*, 17: 733–738. doi:10.1002/gps.677
51. Schalleberger JB, Colet C de F. Assessment of dependence and anxiety among benzodiazepine users in a provincial municipality in Rio Grande do Sul, Brazil. *Trends Psychiatry Psychother*. 2016 Jun;38(2):63–70.
52. Boeuf-Cazou O, Bongue B, Ansiau D, Marquié J-C, Lapeyre-Mestre M. Impact of long-term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort. *Eur J Clin Pharmacol*. 2011;67(10):1045.
53. Rahman F, Lall P, Iqbal S, Vicknasingam B. Pain, instability, and familial discord: a qualitative study into women who use drugs in Malaysia. *Harm Reduct J*. 2015;12(1):52.

54. Paton C. Benzodiazepines and disinhibition: a review. *Psychiatr Bull.* 2002 Dec 1;26(12):460.
55. De Mojá CA, Spielberger CD. Anger and Drug Addiction. *Psychol Rep.* 1997 Aug 1;81(1):152–4
56. Griffin, Charles E. et al. “Benzodiazepine Pharmacology and Central Nervous System–Mediated Effects.” *The Ochsner Journal* 13.2 (2013): 214–223. Print.
57. Magallón-Neri, Ernesto et al. “Personality Psychopathology, Drug Use and Psychological Symptoms in Adolescents with Substance Use Disorders and Community Controls.” Ed. Catherine Myers. *PeerJ* 3 (2015): e992. *PMC*. Web. 9 Nov. 2016.
58. Breggin, Peter R. “Analysis of Adverse Behavioral Effects of Benzodiazepines With a Discussion on Drawing Scientific Conclusions from the FDA's Spontaneous Reporting System.” *The Journal of Mind and Behavior*, vol. 19, no. 1, 1998, pp. 21–49.